Feltl analyst highlights Novadaq and TearLab in WSJ interview
May 10, 2013 by Jennifer Poland · Leave a Comment
The Wall Street Journal has announced its 2012 “Best On The Street” stock picker rankings, with Feltl analyst, Ben Haynor, coming second in the Medical Equipment & Supplies category.
In an interview with the WSJ, Mr. Haynor said TearLab (NASDAQ:TEAR; TSX:TLB) is the “most intriguing stock in my space at the moment.”
He said TearLab is still relatively undiscovered by investors and is early in its roll-out of a first-of-its-kind, point-of-care diagnostic platform to diagnose dry eye disease, which impacts some 30 million Americans. “In my view, they have the Holy Grail in market positioning, with regulatory approvals already secured, reimbursement largely in place, a massive potential market, and essentially no competition.
That really is amazing and worth noting again. A Wall Street Journal top analyst says out of the hundreds of medical device makers ..... TEAR .... is the one that has him the most intrigued. Trust me these guys know when they say such a statement to Wall Street Journal, they are really putting their reputation on the line. So you know he loves TEAR's prospects to put it out there like that !!
Hey timman - is it illegal to spread lies and misconceptions about a stock like you and your shortie friends do about this so called "massive dilution" coming? Last I checked, there hasn't been any announcement about that from the company. Do you have insider information and using it for your financial gain? No? (obviously not...ha ha). So, you're full of $hit. Glad you're about to take a big hit next week when this stock trades above $10 and longs hold on to their shares.